Latest Breaking News On - சந்தைப்படுத்தல் அங்கீகாரம் - Page 3 : comparemela.com

Pfizer and BioNTech Announce Positive Topline Results from

Pfizer and BioNTech Announce Positive Topline Results from
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChristopher stevoSylke maasAlbert bourlaAmy roseUgur sahinFosun pharmaCenters for diseaseDrug administrationBayer animal healthExchange commissionPfizer incEuropean unionEuropean medicines agencyRoche group

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
pfizer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pfizer.com Daily Mail and Mail on Sunday newspapers.

Luye Pharma enters into an agreement with ESTEVE to commercialize an Alzheimer s Disease Multi-Day Treatment Patch in Spain

/PRNewswire/ Luye Pharma Switzerland AG ("Luye Switzerland"), a fully owned subsidiary of Luye Pharma Group (Luye Pharma), and Esteve Pharmaceuticals, S.A..

United statesComunidad autonoma de catalunaLuye pharmaXavier valeraBruno delieLuye pharma groupTowa pharmaceutical co ltdEuropean unionLuye life sciences groupEsteve pharmaceuticalsLuye pharma switzerlandRivastigmine multi day transdermal patchManaging director spainGeneral managerMulti day transdermal patchMarketing authorization

Enzene obtains marketing authorisation for Romiplostim Biosimilar drug in India

BioSpectrum is an integrated B2B media platform for the healthcare and bioscience industry in India and Asia.

Enzene romiplostimHimanshu gadgilEnzene biosciencesSandeep singhAlkem laboratoriesMarketing authorizationDrug controller generalImmune thrombocytopenic purpuraWhole time directorHealthcare managementLife sciencesUs healthcareAsia biotechஹிமான்ஷு காட்கில்சந்தீப் சிங்அல்கெம் ஆய்வகங்கள்

Enzene Biosciences Ltd obtains Marketing Authorization for its Romiplostim Biosimilar drug in India

Pune (Maharashtra) [India], August 20 (ANI/PRNewswire): Enzene Biosciences Ltd. "Enzene" announces a successful Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its second biosimilar drug "Romiplostim", indicated for the treatment of chronic Immune Thrombocytopenic Purpura (ITP) in adults.

Himanshu gadgilEnzene romiplostimSandeep singhAlkem laboratories ltdEnzene biosciences ltdEnzene biosciencesMarketing authorizationDrug controller generalImmune thrombocytopenic purpuraWhole time directorManaging directorDr himanshu gadgilBandeep singhStrategic partnershipsஹிமான்ஷு காட்கில்சந்தீப் சிங்